Cargando…

Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis

BACKGROUND: Cervical cancer is the most common indication for ovarian transposition in reproductive-age women. Ovarian transposition should be performed in premenopausal women undergoing pelvic irradiation to preserve ovarian function, and prevent early menopause. As women become more knowledgeable...

Descripción completa

Detalles Bibliográficos
Autores principales: Laios, Alexandros, Otify, Mohamed, Papadopoulou, Argyro, Gallos, Ioannis D., Ind, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308360/
https://www.ncbi.nlm.nih.gov/pubmed/35869476
http://dx.doi.org/10.1186/s12905-022-01887-8
_version_ 1784752968706293760
author Laios, Alexandros
Otify, Mohamed
Papadopoulou, Argyro
Gallos, Ioannis D.
Ind, Thomas
author_facet Laios, Alexandros
Otify, Mohamed
Papadopoulou, Argyro
Gallos, Ioannis D.
Ind, Thomas
author_sort Laios, Alexandros
collection PubMed
description BACKGROUND: Cervical cancer is the most common indication for ovarian transposition in reproductive-age women. Ovarian transposition should be performed in premenopausal women undergoing pelvic irradiation to preserve ovarian function, and prevent early menopause. As women become more knowledgeable about their fertility options, it is still unclear who will benefit from the intervention. We updated our previous meta-analysis of ovarian function preservation, symptomatic ovarian cysts, and metastases to the transposed ovaries following ovarian transposition in cervical cancer patients to further guide current clinical practice. METHODS: A systematic search of Medline, Embase, Web of Science, and The Cochrane Library databases, dating from January 1980 to July 2021, was conducted. We computed the summary proportions of women who had ovarian function preservation, non-ovarian cyst formation and metastases to the transposed ovaries following ovarian transposition by random-effects meta-analysis and we explored study heterogeneity by type of radiotherapy. RESULTS: There were 29 publications reporting on 1160 women with cervical cancer who underwent ovarian transposition. In the group that underwent surgery alone, 91% of the women had preserved ovarian function (95% CI 83–100), 89% (95% CI 80–99) of women who did not develop ovarian cysts, and 99% (95% CI 1–5) of women who did not suffer metastases to the transposed ovaries. In the surgery ± brachytherapy (BR) group, the proportion of women with the preserved ovarian function was 93% (95% CI 76–113), 84% (95% CI 69–103) of women who did not develop ovarian cysts, and 99% (95% CI 82–120) of women who did not suffer metastases to the transposed ovaries. In the external beam pelvic radiotherapy (EBRT) ± BR ± surgery group, the proportion of women with the preserved ovarian function was 61% (95% CI 55–69), and 95% (95% CI 85–107) of women who developed ovarian cysts. There were no metastases to the transposed ovaries in that group. CONCLUSIONS: In women with cervical cancer, ovarian transposition offers a significant preservation of the ovarian function. Despite an expected incidence of ovarian cyst formation, it carries almost no risk for metastases to the transposed ovaries.
format Online
Article
Text
id pubmed-9308360
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93083602022-07-24 Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis Laios, Alexandros Otify, Mohamed Papadopoulou, Argyro Gallos, Ioannis D. Ind, Thomas BMC Womens Health Research BACKGROUND: Cervical cancer is the most common indication for ovarian transposition in reproductive-age women. Ovarian transposition should be performed in premenopausal women undergoing pelvic irradiation to preserve ovarian function, and prevent early menopause. As women become more knowledgeable about their fertility options, it is still unclear who will benefit from the intervention. We updated our previous meta-analysis of ovarian function preservation, symptomatic ovarian cysts, and metastases to the transposed ovaries following ovarian transposition in cervical cancer patients to further guide current clinical practice. METHODS: A systematic search of Medline, Embase, Web of Science, and The Cochrane Library databases, dating from January 1980 to July 2021, was conducted. We computed the summary proportions of women who had ovarian function preservation, non-ovarian cyst formation and metastases to the transposed ovaries following ovarian transposition by random-effects meta-analysis and we explored study heterogeneity by type of radiotherapy. RESULTS: There were 29 publications reporting on 1160 women with cervical cancer who underwent ovarian transposition. In the group that underwent surgery alone, 91% of the women had preserved ovarian function (95% CI 83–100), 89% (95% CI 80–99) of women who did not develop ovarian cysts, and 99% (95% CI 1–5) of women who did not suffer metastases to the transposed ovaries. In the surgery ± brachytherapy (BR) group, the proportion of women with the preserved ovarian function was 93% (95% CI 76–113), 84% (95% CI 69–103) of women who did not develop ovarian cysts, and 99% (95% CI 82–120) of women who did not suffer metastases to the transposed ovaries. In the external beam pelvic radiotherapy (EBRT) ± BR ± surgery group, the proportion of women with the preserved ovarian function was 61% (95% CI 55–69), and 95% (95% CI 85–107) of women who developed ovarian cysts. There were no metastases to the transposed ovaries in that group. CONCLUSIONS: In women with cervical cancer, ovarian transposition offers a significant preservation of the ovarian function. Despite an expected incidence of ovarian cyst formation, it carries almost no risk for metastases to the transposed ovaries. BioMed Central 2022-07-22 /pmc/articles/PMC9308360/ /pubmed/35869476 http://dx.doi.org/10.1186/s12905-022-01887-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Laios, Alexandros
Otify, Mohamed
Papadopoulou, Argyro
Gallos, Ioannis D.
Ind, Thomas
Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis
title Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis
title_full Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis
title_fullStr Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis
title_full_unstemmed Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis
title_short Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis
title_sort outcomes of ovarian transposition in cervical cancer; an updated meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308360/
https://www.ncbi.nlm.nih.gov/pubmed/35869476
http://dx.doi.org/10.1186/s12905-022-01887-8
work_keys_str_mv AT laiosalexandros outcomesofovariantranspositionincervicalcanceranupdatedmetaanalysis
AT otifymohamed outcomesofovariantranspositionincervicalcanceranupdatedmetaanalysis
AT papadopoulouargyro outcomesofovariantranspositionincervicalcanceranupdatedmetaanalysis
AT gallosioannisd outcomesofovariantranspositionincervicalcanceranupdatedmetaanalysis
AT indthomas outcomesofovariantranspositionincervicalcanceranupdatedmetaanalysis